Collaboration Deals With Pharma May Be Preferable To Licensing For Biotech
Executive Summary
Biotechs may want to look at deal structures with pharmaceutical companies outside of the traditional licensing model in order to have greater control over the development process, Medarex Senior Director of Development Melinda Shockley said at the recent Drug Information Association annual meeting in Philadelphia